ヘモクロマトーシス（鉄過剰症）疾患治療の世界市場予測（2022年～2027年）

世界のヘモクロマトーシス（鉄過剰症）疾患治療の市場規模は、2020年に252億4,100万米ドルとなり、予測期間中に2.84％のCAGRで成長し、2027年に306億9,800万米ドルになると予測されています。

当レポートでは、世界のヘモクロマトーシス（鉄過剰症）疾患治療市場について調査し、市場規模や予測、COVID-19の影響、市場の促進要因および課題、市場動向、セグメント別の市場分析、競合情勢、主要企業のプロファイルなどの体系的な情報を提供しています。

目次

第1章 イントロダクション

• 市場概要
• COVID-19の影響
• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 前提条件

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• 業界のバリューチェーン分析

第5章 ヘモクロマトーシス（鉄過剰症）疾患治療市場：タイプ別

• イントロダクション
• 遺伝性ヘモクロマトーシス
• 後天性ヘモクロマトーシス

第6章 ヘモクロマトーシス（鉄過剰症）疾患治療市場：治療別

• イントロダクション
• 治療的瀉血
• 鉄キレート療法
• その他

第7章 ヘモクロマトーシス（鉄過剰症）疾患治療市場：エンドユーザー別

• イントロダクション
• 病院
• 外科センター
• その他

第8章 ヘモクロマトーシス（鉄過剰症）疾患治療市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • その他
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • その他
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場の有利性
• 合併、買収、契約、コラボレーション
• ベンダーの競合マトリックス

第10章 企業プロファイル

• Protagonist Therapeutics
• Silence Therapeutics
• Disc Medicine
• Bond Biosciences
• Novartis Pharmaceuticals Corporation
• Pfizer Inc.

The Hemochromatosis (Iron overload) disease treatment market is projected to grow at a CAGR of 2.84% during the forecast period to reach US$30.698 billion by 2027, from US$25.241 billion in 2020.

The unusual accumulation of iron in the parenchymal organ is known as hemochromatosis. The overaccumulation of iron leads to a toxic condition in the organs. In these conditions, iron accumulates abnormally in the parenchymal organs. Excessive absorption of iron in the body causes organ toxicity. Hemochromatosis can be detected using chest x-rays, echocardiography, CT scans, and possibly imaging tests such as MRI. Patients with hemochromatosis can be evaluated using diagnostic endoscopy, skin endoscopy, and liver biopsy. Primary hemochromatosis (hereditary) and secondary hemochromatosis are the two most common types of hemochromatosis. Secondary hemochromatosis develops because of anaemia, liver disease, or other illnesses such as heavy blood transfusions. Hemochromatosis is more common in men than women because menstruation causes monthly blood loss in women. As a result, women accumulate iron more slowly than men.

The hemochromatosis treatment market is anticipated to rise as a result of early illness detection and higher expenditure in R&D activities.

Early disease detection and increased financial investment in Research & Development activities by industry participants are expected to drive the growth of the global hemochromatosis treatment market during the forecasted period. Increasing R&D technologies with high-tech treatment options, on the other hand, will heighten numerous opportunities that will begin to germinate in the global hemochromatosis treatment market during the forecast period. The presence of anemia in women is expected to drive the growth of the hemochromatosis treatment market. According to WHO, the anemia prevalence in reproductive-age women was 29.9 percent, 36.5 percent in pregnant women, and 29.6 percent in non-pregnant women in 2019. The percentage varies by region, with the highest increase in percentage seen in Southern Asia, Central Asia, and Sub-Saharan Africa, and the lowest in Europe and North America.

The hemochromatosis treatment market is driven primarily by dramatic lifestyle changes, along with changing climatic conditions.

Stressful lifestyles may lead to many mutations that cause hemochromatosis and, ultimately, iron accumulation. Rapid climate change can also cause hemochromatosis. Nowadays, a considerable lifestyle change that has grown extra traumatic may also result in a slew of mutations that result in hemochromatosis and iron accumulation. If hemochromatosis isn't regarded and handled early on, it may broaden to the most critical issues consisting of liver damage, diabetes, arthritis, reproductive issues, and cardiovascular disease. Blood investigation and thorough bodily examinations are used to diagnose it.

However, lack of awareness of the disease and signs of less apparent symptoms can limit the hemochromatosis treatment market.

By 2027, the phlebotomy treatment segment is expected to have the largest market share.

Hemochromatosis has been treated by phlebotomy, chelation therapy, and surgery. Phlebotomy, which requires taking out excess iron from the blood, is used to cure hemochromatosis. This procedure has kept the iron blood levels in check by taking blood from the patient's body regularly. It is the same as blood donation. Phlebotomy is simple, low-cost, and risk-free. Like regular blood donation, phlebotomy is primarily performed in blood banks.

North America is expected to have a sizeable market share in the hemochromatosis treatment market.

Due to the advancements in hemochromatosis diagnosis methods, North America is expected to have the largest market share in the hemochromatosis treatment industry. Europe is expected to be followed by North America due to increased invested capital in hemochromatosis treatment research and development. While the Asia Pacific is expected to grow rapidly owing to the increasingly significant presence of major players in the market and rising treatment costs and availability. During the forecast period, Asia Pacific is expected to proliferate owing to global population movements, rising living standards, and a more technologically inclined population, which are causing genetic changes that may cause the hemochromatosis treatment market in the Asia Pacific region.

Key Developments

• In August 2022, Disc Medicine and Gemeini Therapeutics Inc. announced a merger to create a NASDAQ-listed, clinical-stage biopharmaceutical company focused on expanding Disc's portfolio of hematology programs. The Hematology portfolio includes a Matriptase-2 inhibitor research program. The therapeutic role of hepcidin has been established in hereditary hemochromatosis patients and it's being studied for the treatment of diseases associated with iron overload.
• Bond Biosciences announced the closing of Series B financing to accelerate manufacturing timelines for BBI-001 and pipeline development in January 2022. The BBI-001 is an investigational new drug which is initially developed to treat iron overload associated with Hereditary Hemochromatosis. This recent development is expected to strengthen the development program for BBI-001 and advance the pipeline of non-absorbed oral therapies, claims the company.

COVID-19 Impact on Hemochromatosis (Iron Overload) Diseases Treatment Market

To accommodate patients with COVID-19 and limit the transmission of disease, acute hospital services were reorganized. The non-essential patient and outpatient care were halted temporarily. Consequently, the pandemic had an adverse impact on the hemochromatosis (iron overloaded) treatment market.

Segmentation

• By Type

Hereditary Hemochromatosis

Acquired Hemochromatosis

• By Treatment

Therapeutic Phlebotomy

Iron Chelation Therapy

Others

• By End-users

Hospitals

Surgical Centers

Others

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• United Kingdom
• Spain
• Others

The Middle East and Africa

• Saudi Arabia
• UAE
• Others

Asia Pacific

• China
• India
• Japan
• South Korea
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. COVID-19 Scenario
• 1.3. Market Definition
• 1.4. Market Segmentation

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. HEMOCHROMATOSIS (IRON OVERLOAD) DISEASES TREATMENT MARKET, BY TYPE

• 5.1. Introduction
• 5.2. Hereditary Hemochromatosis
• 5.3. Acquired Hemochromatosis

6. HEMOCHROMATOSIS (IRON OVERLOAD) DISEASES TREATMENT MARKET, BY TREATMENT

• 6.1. Introduction
• 6.2. Therapeutic Phlebotomy
• 6.3. Iron Chelation Therapy
• 6.4. Others

7. HEMOCHROMATOSIS (IRON OVERLOAD) DISEASES TREATMENT MARKET, BY END-USERS

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Surgical Centers
• 7.4. Others

8. HEMOCHROMATOSIS (IRON OVERLOAD) DISEASES TREATMENT MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrative
• 9.3. Mergers, Acquisition, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Protagonist Therapeutics
• 10.2. Silence Therapeutics
• 10.3. Disc Medicine
• 10.4. Bond Biosciences
• 10.5. Novartis Pharmaceuticals Corporation
• 10.6. Pfizer Inc.